Geron Corporation or Novavax, Inc.: Who Invests More in Innovation?

Innovation Investment: A Tale of Two Biotechs

In the competitive world of biotechnology, innovation is key. Over the past decade, Geron Corporation and Novavax, Inc. have been at the forefront of this race, each investing heavily in research and development (R&D). From 2014 to 2023, Novavax consistently outpaced Geron, with R&D expenses peaking in 2021 at over 2.5 billion dollars, a staggering 1,900% increase from 2014. In contrast, Geron's R&D spending grew by approximately 500% over the same period, reaching its highest in 2023. This trend highlights Novavax's aggressive push in innovation, particularly during the COVID-19 pandemic, which likely fueled its R&D surge. Meanwhile, Geron's steady increase reflects a more conservative yet consistent approach. As these companies continue to innovate, their R&D investments will be crucial in shaping the future of biotechnology.